Please login to the form below

Not currently logged in
Email:
Password:

naloxegol

This page shows the latest naloxegol news and features for those working in and with pharma, biotech and healthcare.

FDA approves Synergy's constipation drug Trulance

FDA approves Synergy's constipation drug Trulance

The latter indication is also targeted by AstraZeneca's Movantik (naloxegol), recently sold to ProStrakan in Europe where it is marketed as Moventig.

Latest news

  • AstraZeneca sells rights to seven anaesthetics in $770m deal AstraZeneca sells rights to seven anaesthetics in $770m deal

    Valeant. ProStraken obtained the European rights to AZ's opioid-induced constipation treatment Moventig (naloxegol), and the firm sold Entocort (budesonide), its inflammatory bowel disease therapy, to Tillotts Pharma.

  • AZ sells Zurampic rights to Gruenenthal for $230m AZ sells Zurampic rights to Gruenenthal for $230m

    In recent months the company has sold late-stage psoriasis candidate brodalumab to Valeant, transferred European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and divested ex-US

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    Most recently, the pharma group sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to Scottish firm ProStrakan, a subsidiary of Japan's Kyowa Hakko Kirin, for an upfront

  • AZ and Daiichi Sankyo sign Movantik marketing deal AZ and Daiichi Sankyo sign Movantik marketing deal

    AstraZeneca has announced a new co-commercialisation agreement with Daiichi Sankyo for the constipation drug Movantik (naloxegol) in the US.

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics